Side-by-side · Research reference
TesofensinevsTirzepatide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3Draft10/40 cited
BFDA-ApprovedVerified14/45 cited
Tesofensine
SNDRI · Phase 3 obesity candidate
Oral · Once daily morning
Tirzepatide
GIP+GLP-1 Dual Agonist · FDA-Approved
SQ · Abdomen / thigh / arm · Once weekly
01Mechanism of Action
Parameter
Tesofensine
Tirzepatide
Primary target
Serotonin / norepinephrine / dopamine transporters (SERT / NET / DAT)Astrup 2008
GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018
Pathway
Triple monoamine reuptake inhibition → ↑synaptic 5-HT, NE, DA → appetite suppression + thermogenesisAstrup 2008
Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022Frias 2018
Downstream effect
Strong appetite suppression, mild thermogenic effect, weight lossAstrup 2008
Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022
Feedback intact?
—
Glucose-dependent insulin release preserves physiological feedback
Origin
Small molecule developed by NeuroSearch (Denmark) for CNS indications, repurposed for obesityAstrup 2008
39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018
Antibody development
—
—
02Dosage Protocols
Parameter
Tesofensine
Tirzepatide
Frequency
Once daily, morning
—
Lower / starter dose
0.125 mg / day
—
Evidence basis
Phase 2b + ongoing Phase 3Astrup 2008
FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022ZEPBOUND (tirzepatide) injecti 2023
Duration
24 weeks per studied cycle
Indefinite for chronic indication
Form
Oral capsule
—
Timing
Morning to avoid sleep disruption
Once weekly, any time of day
Standard dose (weight)
—
5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023Jastreboff 2022
Titration schedule
—
2.5 mg → +2.5 mg every 4 weeks → 15 mg max
Slower titration mitigates GI side effects.
Reconstitution
—
Pre-filled commercial pen. Research vial: bacteriostatic water per label.
04Side Effects & Safety
Parameter
Tesofensine
Tirzepatide
Insomnia
Dose-related; mitigate with morning timing
—
Dry mouth
Common
—
Nausea
Common
—
Mood changes
Anxiety / agitation possible
—
Cardiovascular events
Phase 3 trial monitoring; not yet FDA-cleared
—
Pregnancy / OB
Contraindicated
Contraindicated
Injection site reaction
—
Mild erythema, pruritus
Thyroid C-cell tumours
—
Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023
Hypoglycemia
—
Low as monotherapy; risk with sulfonylureas / insulin
Gallbladder events
—
Increased cholelithiasis
Diabetic retinopathy
—
Rapid glycemic improvement may transiently worsen
Absolute Contraindications
Tesofensine
- ·Pregnancy / breastfeeding
- ·Severe cardiovascular disease
- ·Concurrent MAOI use
Tirzepatide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to tirzepatide
Relative Contraindications
Tesofensine
- ·Hypertension
- ·Anxiety disorder
- ·Insomnia
Tirzepatide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Diabetic retinopathy
05Administration Protocol
Parameter
Tesofensine
Tirzepatide
1. Form
Oral capsule (investigational; not commercial).
Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.
2. Administration
Swallow whole with water, morning only.
SQ — abdomen, thigh, or upper arm. Rotate weekly.
3. Timing
Morning to mitigate insomnia. Do not dose evening.
Once weekly, same day. Day change allowed if ≥3 days separate doses.
4. Storage
Room temp ≤25 °C, dry place.
Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.
5. Caveat
Monitor BP + HR + mood. Avoid stimulants + MAOIs.
Pen-supplied. Research vial: 27–31G insulin syringe.